Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 217 of 5804
-
Could Two-Drug cocktails tame stubborn inflammatory bowel disease?
Disease control Not yet recruitingCrohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New Two-Drug combo aims to beat back returning myeloma
Disease control Not yet recruitingThis phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Teclistamab is a bispecific an…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for cancer survivors: drug aims to shield against Life-Threatening infections
Disease control Not yet recruitingThis is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapi…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New eye drug targets fluid buildup to fight glaucoma
Disease control Not yet recruitingThis study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for AML patients: Triple-Drug combo targets Tough-to-Treat leukemia
Disease control Not yet recruitingCancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also pr…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for lymphoma patients: glofitamab combo faces standard care in trial
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (GemOx) versus standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who have relapsed early (within 1 y…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo therapy offers hope for hard-to-treat nose cancer
Disease control Recruiting nowRe-irradiation is the most common clinical treatment for recurrent nasopharyngeal carcinoma; however, it is associated with severe complications which seriously affect patients' quality of life. Exploring deferred salvage radiotherapy until nasopharyngeal or cervical progression…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Which PAH treatment strategy works better: adding a third drug or increasing the dose?
Disease control Recruiting nowPulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by increased pressure in the pulmonary arteries, leading to right heart failure and premature death. Although combination therapy has improved outcomes, many patients remain at intermediate or h…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can pressurized oxygen boost stroke recovery?
Disease control Recruiting now1. The goal of this clinical trial is to evaluate the efficacy and safety of hyperbaric oxygen (HBO)in stroke patients after endovascular treatment 2. The main questions it aims to answer is: Whether HBO can improve the prognosis of ischemic stroke patients after endovascular…
Phase: NA • Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Promising new combo for tough lung cancer: Low-Dose radiation plus immunotherapy
Disease control Not yet recruitingThis study is a multicenter, prospective investigation aiming to evaluate the efficacy and safety of low-dose radiotherapy (15Gy/1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy concurrently with Adebrelimab, followed by Adebrelimab maintenance therapy…
Phase: PHASE2 • Sponsor: Jiangmen Central Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Recruiting nowThe upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and pat…
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can zapping an extra vein stop atrial fibrillation better?
Disease control Recruiting nowAtrial fibrillation (AF) is one of the most concerning diseases in the field of cardiac arrhythmias. It is a type of rapid supraventricular arrhythmia characterized by rapid and disorganized contraction of the atria, which leads to ventricular rate disturbance, impaired cardiac f…
Phase: NA • Sponsor: Qiang Hu • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New study aims to tame dangerous immune reaction in myeloma therapy
Disease control Recruiting nowThe purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Tiny drug particles aim to shrink breast tumors
Disease control Not yet recruitingThe goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The…
Phase: PHASE2 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets HPV-Driven cancers in phase II trial
Disease control Not yet recruitingThis trial is a multicenter, open-label, dose exploration and cohort expansion Phase II clinical study designed to evaluate the safety, immunogenicity, and preliminary efficacy of different dosing regimens of SYS6026 injection (hereinafter referred to as "SYS6026") combined with …
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Blood filter may tame deadly inflammation after heart attack
Disease control Not yet recruitingCardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunctio…
Phase: NA • Sponsor: Leipzig Heart Science gGmbH • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
Disease control Not yet recruitingMirvetuximab soravtansine (MIRV) is an antibody-drug conjugate approved for the treatment of ovarian cancer. However, real-world data on its safety and effectiveness in routine clinical practice are limited, especially in the Chinese patient population. MIRAS is a multicenter, pr…
Sponsor: NING LI-GYN • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Wobble training could help stroke survivors regain balance
Disease control Not yet recruitingThis study innovatively proposes an "environment-perturbation balance training (E-PBT)" intervention, which delivers stable, graded environmental perturbations to keep the challenges within the manageable range. This approach can significantly reduce fear, align with the psycholo…
Phase: NA • Sponsor: First People's Hospital of Shenyang • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a zapping helmet ease Parkinson's tremors and speech problems?
Disease control Recruiting nowThis clinical trial will evaluate the efficacy of accelerated Temporal Interference Stimulation (TIS) as a therapeutic intervention for individuals diagnosed with Parkinson's disease. Different frequency TIS will be delivered targeting the bilateral subthalamic nuclei of the brai…
Phase: NA • Sponsor: Ke Dong, MD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New HPV vaccine aims to shield against extra cancer types
⭐️ VACCINE ⭐️ Not yet recruitingResearchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. A standard vaccine to prevent HPV-related cancers is V503. V503 protects against 9 types of HP…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:06 UTC